Kathleen Smith
Dermatopathology · Decatur, GANPI 1396916219
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,523 of the $57,109 with a category attached, or 64.0%. AbbVie accounts for 69.1% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $17,664 and has fallen 73.4% since, to $4,700 in 2025. Among dermatopathology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 956 payments — averaging $59.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$39K
- Novartis$7K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$2K
- Pfizer$1K
- Lilly USA, LLC$1K
- plus $5K from 26 others
What the payments were for
- Speaking & faculty fees$36,52364%
- Travel & lodging$3,5276%
- Food & beverage$16,58229%
- Education$4771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 320 | $39,455 |
| Novartis | 98 | $6,834 |
| Regeneron Healthcare Solutions, Inc. | 71 | $1,781 |
| Sanofi | 59 | $1,516 |
| Pfizer | 88 | $1,255 |
| Lilly USA, LLC | 51 | $1,193 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 67 | $1,010 |
| Johnson & Johnson | 40 | $885 |
| UCB, Inc. | 39 | $726 |
| LEO Pharma Inc. | 23 | $494 |
| Sun Pharmaceutical Industries Inc. | 16 | $389 |
| Dermavant Sciences, Inc. | 19 | $233 |
| Incyte Corporation | 8 | $162 |
| Amgen | 7 | $136 |
| Organon | 7 | $131 |
| Biogen | 1 | $107 |
| Sandoz | 5 | $104 |
| Helsinn Therapeutics (U.S.), Inc. | 5 | $79 |
| Phadia US Inc. | 4 | $68 |
| Arcutis Biotherapeutics, Inc. | 3 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $64 |
| Genentech USA, Inc. | 4 | $63 |
| Galderma Laboratories, L.p. | 3 | $54 |
| Biocon Biologics Inc | 2 | $48 |
| Mayne Pharma Commercial LLC | 3 | $47 |
| Prugen, Inc. Pharmaceuticals | 2 | $44 |
| Boehringer Ingelheim | 2 | $42 |
| LNHC, Inc | 1 | $39 |
| Merck | 2 | $26 |
| AstraZeneca | 1 | $22 |
| Fidia Pharma USA Inc. | 1 | $20 |
| Almirall LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,109 in reported general payments places this provider in the 95th percentile of 25 dermatopathology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 28 | $351,225 |
| Dupixent PenDupilumab | 46 | $180,192 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $137,461 |
| Humira PenAdalimumab | 11 | $136,154 |
| RinvoqUpadacitinib | 16 | $109,213 |
| Taltz AutoinjectorIxekizumab | 11 | $74,853 |
| OpzeluraRuxolitinib Phosphate | 25 | $49,903 |
| Tretinoin | 135 | $10,814 |
| Ketoconazole | 497 | $8,518 |
| Betamethasone Valerate | 298 | $8,133 |
| Clobetasol Propionate | 184 | $7,371 |
| Tacrolimus | 37 | $6,292 |
| Pimecrolimus | 22 | $5,389 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 90 | $5,162 |
| Triamcinolone Acetonide | 386 | $4,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $39,455 | $109,21316 claims |
| Incyte CorporationOpzelura | $162 | $49,90325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 dermatopathology providers in Georgia.
Other dermatopathology in Decatur
- Drazen JukicSavannah$16K
- Dipti AnandSmyrna$11K
- Jill Buckthal-MccuinGreensboro$11K
- Gautham VellaichamyAtlanta$2K
- Meera BrahmbhattMarietta$2K
- Andrea VolkAtlanta$497
- Paul HillesheimRome$448
- Wesley SimmsThomasville$396
- Melinda MohrAtlanta$380
- Kristopher McKaySmyrna$344
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.